ASCO Breakthrough 2026 Spotlights AI Tumor Boards and MRD-Guided Therapy

What Happened

ASCO Breakthrough 2026 devoted its second day to artificial intelligence applications in oncology and minimal residual disease monitoring, with sessions covering AI-driven tumor boards, clinical trial matching, and ctDNA-guided therapy adjustments, according to reporting by CancerNetwork. The conference, organized by the American Society of Clinical Oncology, highlighted these technologies as active components of cancer care workflows rather than experimental concepts.

Background

ASCO Breakthrough is a dedicated conference within ASCO's annual programming that focuses on emerging technologies and their application to cancer treatment. Minimal residual disease, or MRD, refers to small numbers of cancer cells that remain in a patient after treatment. Circulating tumor DNA, or ctDNA, is a blood-based biomarker used to detect and track those remaining cells without invasive tissue biopsies. Both MRD and ctDNA testing have been subjects of increasing clinical interest as tools for determining whether to continue, adjust, or de-escalate therapy following initial treatment.

AI-driven tumor boards represent a shift in how multidisciplinary clinical teams review patient cases. Traditional tumor boards bring together oncologists, radiologists, pathologists, and other specialists to review cases in scheduled group meetings. AI-assisted versions of these boards use algorithms to aggregate patient data, flag relevant clinical trial options, and surface treatment recommendations ahead of or during those meetings.

Clinical trial matching is a related application in which AI systems cross-reference a patient's molecular profile, diagnosis, treatment history, and eligibility criteria against available trial databases to identify candidates who might qualify for experimental therapies. Manual trial matching has historically been time-intensive and inconsistent across institutions.

What Was Covered at the Conference

Day two sessions at ASCO Breakthrough 2026 addressed how MRD and ctDNA results are being integrated into treatment decision points, including decisions about whether patients who test MRD-negative following chemotherapy or immunotherapy require additional intervention. Presentations also examined the use of AI platforms to reduce the time between diagnosis and treatment initiation by accelerating the data aggregation steps that precede clinical decisions.

The conference sessions did not announce specific product approvals or regulatory designations. Coverage from CancerNetwork described the presentations as reflecting a broader institutional movement toward embedding these tools into standard oncology practice, with multiple health systems and academic cancer centers reporting active use or pilot deployments.

Trial matching was discussed in the context of access equity, with presenters noting that patients at smaller or community-based cancer centers have historically had lower rates of clinical trial enrollment compared with those at large academic medical centers. AI-based matching tools were presented as one mechanism for narrowing that gap by reducing the administrative burden on clinicians at lower-resource sites.

The Role of ctDNA in Therapy Guidance

Several presentations at the conference examined protocols in which ctDNA levels are used as a real-time signal to guide therapy intensity. In some models being studied, a patient who clears detectable ctDNA earlier than expected may have their treatment course shortened, while one who retains detectable ctDNA may be escalated to a more aggressive regimen. These adaptive approaches remain under clinical investigation and are not yet standard of care across tumor types, but multiple ongoing trials are evaluating their validity in colorectal, lung, and breast cancers.

The integration of AI into this workflow involves processing serial ctDNA measurements alongside imaging data, pathology results, and treatment records to generate decision-support outputs for oncologists. Presenters noted that the accuracy and clinical utility of such systems depend on the quality and completeness of the underlying data.

What Comes Next

ASCO Breakthrough 2026 continues with additional sessions scheduled to address regulatory pathways for AI-based oncology tools and the evidentiary standards required for MRD-guided therapy protocols to achieve formal clinical guideline endorsement.